by: Parent Project Muscular Dystrophy
Members of the Solid Biosciences team recently joined PPMD for a community webinar to review initial positive data from the INSPIRE DUCHENNE study of SGT-003, a next-generation microdystrophin gene therapy candidate. The Solid team provided a current update on the study, including microdystrophin expression and biomarker results from participants who have reached the Day 90 timepoint, as well as a safety update from the first six participants dosed. In addition, Solid outlined plans for continued dosing in the expanded phase 1/2 study.
